🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
INCY
NASDAQ
🇺🇸 US
Incyte Corporation
Pharmaceuticals
14Score
DipBuster Score™
$115.65
$1.6 (-1.36%)
Live price · Source: Yahoo
52-Week Position
$67.17
92% of range
$119.60
Beta
0.758
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.758
52W High$119.60
52W Low$67.17
DipBuster Brief
Key signals at a glance
Zone: Sell / Avoid
Bearish
Near 52-Week High — Asymmetric Risk
At 92% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position92% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.758
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Incyte Corporation (INCY), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-07-02 | Mayes Patrick A | SELL | 350 |
| 2026-07-02 | Tray Thomas | SELL | 477 |
| 2026-07-02 | Stein Steven H | SELL | 2,177 |
| 2026-07-02 | Meury William | SELL | 4,779 |
| 2026-06-30 | Clancy Paul J | BUY | 252 |
| 2026-06-30 | Harrigan Edmund | BUY | 255 |
| 2026-06-30 | Baker Bros. Advisors Lp | BUY | 400 |
| 2026-06-30 | Baker Bros. Advisors Lp | BUY | 400 |
| 2026-06-08 | High Katherine A | BUY | 6,111 |
| 2026-06-08 | High Katherine A | BUY | 1,642 |
Graham NCAV Analysis
Above net-net level
Current Assets$5.02B
Less: Total Liabilities−$1.79B
= Net Current Asset Value$3.23B
NCAV Per Share$16.2925
Current Price$117.93
Price / NCAV7.24×
Margin of Safety-623.8%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.758
Dividend/yrNone
52W High$119.60
52W Low$67.17
52-Week Range
$67.17Now$119.60
92% through annual range
From 52W High−3.3%
From 52W Low+72.2%
📖 Plain English Summary
Incyte Corporation is at 92% of its 52-week range. Beta 0.758 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for INCY
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — INCY
Heuristic · balance sheet, insider filings, price data, academic research
Incyte Corporation — DipBuster Score 14/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Incyte Corporation free
Add INCY to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
3/25
Momentum & Volume
6/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 14/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and po…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
William J. Meury
Staff
2,844 employees
Website